Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 12,500 shares on November 26, 2025, marking a total net reduction of 383,500 shares over the past five trading days and 735,500 shares over the past twenty trading days [1][2] - As of now, southbound funds hold 53,061,100 shares of Qiming Medical-B, which accounts for 12.02% of the company's total issued ordinary shares [1][2] Group 2 - Qiming Medical Co., Ltd. specializes in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [2] - The company's product line includes devices for interventional treatment of various heart valve diseases, such as aortic valve, pulmonary valve, mitral valve, and tricuspid valve, as well as systems for radiofrequency ablation and ultrasound ablation for hypertension treatment [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolism protection device, with operations in both domestic and overseas markets [2]
启明医疗-B（02500.HK）：11月26日南向资金减持1.25万股